BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37823937)

  • 1. Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity.
    Cheng X; Wang W; Zhang Z; Zhang H; Zhu P; He R; Wu M; Zhou T; Jiang Y; Jiang L; Chen Y; Liang Z; Wu X; Weng X
    Hepatol Int; 2024 Apr; 18(2):582-594. PubMed ID: 37823937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma.
    Cheng X; Tan X; Wang W; Zhang Z; Zhu R; Wu M; Li M; Chen Y; Liang Z; Zhu P; Wu X; Weng X
    Cancer Res; 2023 Feb; 83(4):582-594. PubMed ID: 36512635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TOX promotes the exhaustion of antitumor CD8
    Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
    J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner.
    Yi Y; He HW; Wang JX; Cai XY; Li YW; Zhou J; Cheng YF; Jin JJ; Fan J; Qiu SJ
    J Hepatol; 2013 May; 58(5):977-83. PubMed ID: 23262246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review.
    Hu B; Lin JZ; Yang XB; Sang XT
    Cell Prolif; 2020 Mar; 53(3):e12772. PubMed ID: 32003505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
    Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-24 Limits Tumor-Infiltrating T Helper 17 Cell Response in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Zhang M; Zhao H; Gao H
    Viral Immunol; 2022 Apr; 35(3):212-222. PubMed ID: 35099297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.
    Sun R; Li J; Lin X; Yang Y; Liu B; Lan T; Xiao S; Deng A; Yin Z; Xu Y; Xiang Z; Wu B
    Front Immunol; 2023; 14():1079495. PubMed ID: 37077908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
    Tan AT; Yang N; Lee Krishnamoorthy T; Oei V; Chua A; Zhao X; Tan HS; Chia A; Le Bert N; Low D; Tan HK; Kumar R; Irani FG; Ho ZZ; Zhang Q; Guccione E; Wai LE; Koh S; Hwang W; Chow WC; Bertoletti A
    Gastroenterology; 2019 May; 156(6):1862-1876.e9. PubMed ID: 30711630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.
    Yan F; Zhang Q; Shi K; Zhang Y; Zhu B; Bi Y; Wang X
    Front Cell Infect Microbiol; 2023; 13():1152987. PubMed ID: 37201112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive CD10
    Meng Y; Ye F; Nie P; Zhao Q; An L; Wang W; Qu S; Shen Z; Cao Z; Zhang X; Jiao S; Wu D; Zhou Z; Wei L
    J Hepatol; 2023 Dec; 79(6):1435-1449. PubMed ID: 37689322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Loaded Tumor-Derived Microparticles Elicit CD8+ T Cell-Mediated Anti-Tumor Response in Hepatocellular Carcinoma.
    Chen Y; Zhang Y; Wang J; Cai X; Chen J; Min X; Xu Y; Qin Q; Wan C
    Int J Nanomedicine; 2024; 19():2227-2239. PubMed ID: 38465206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Lipids of Patients with Hepatitis B and C and Associated Hepatocellular Carcinoma.
    Haberl EM; Weiss TS; Peschel G; Weigand K; Köhler N; Pauling JK; Wenzel JJ; Höring M; Krautbauer S; Liebisch G; Buechler C
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular insight into T cell exhaustion in hepatocellular carcinoma.
    Zhu Y; Tan H; Wang J; Zhuang H; Zhao H; Lu X
    Pharmacol Res; 2024 May; 203():107161. PubMed ID: 38554789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.